Point-Of-Care Molecular Diagnostics: A Leading Driver Behind Rising Respiratory Infections Drive Demand For Point-Of-Care Molecular Diagnostics Market Expansion in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Point-Of-Care Molecular Diagnostics Industry Market Size Be by 2025?
Recent years have seen swift expansion of the point-of-care molecular diagnostics market, with its size set to increase from $3.55 billion in 2024 to $3.98 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.0%. The historical growth witnessed in this market can be ascribed to the rising necessity for quick disease diagnosis, escalation in infectious disease outbreaks, the proliferation of telemedicine and remote testing, regulatory backing for point-of-care diagnostics, and the growing demand for personalized and precision medicine.

What's the Long-Term Growth Forecast for the Point-Of-Care Molecular Diagnostics Market Size Through 2029?
The market size for point-of-care molecular diagnostics is projected to experience substantial growth in the coming years, reaching a value of $6.92 billion in 2029, with a 14.8% compound annual growth rate (CAGR). The expansion during the forecast period is mainly due to the miniaturization of diagnostic tools, proliferation of point-of-care testing for cancer and genetic diseases, bespoke molecular diagnostics for a variety of uses, the incorporation of artificial intelligence and machine learning for data crunching, and acuteness of infectious disease monitoring. Key trends in the forecast period are the utilization of lab-on-a-chip and microfluidic technologies, implementation of digital health and diagnostics via smartphones, point-of-care solutions for COVID-19 and future pandemic readiness, advanced predictive diagnostics powered by AI, and molecular testing using CRISPR technology.

View the full report here:
https://www.thebusinessresearchcompany.com/report/point-of-care-molecular-diagnostics-global-market-report

What Are the Key Growth Drivers Fueling the Point-Of-Care Molecular Diagnostics Market Expansion?
The escalating prevalence of infectious and respiratory ailments is projected to substantially bolster the growth of the point-of-care molecular diagnostics market. Microorganisms that impact the respiratory system cause respiratory infections like viruses or bacteria. These pathogens can be transmitted through actions like coughing, sneezing, or even direct contact. The range of treatments for severe respiratory diseases includes various inhalers, oral medicines, intravenous therapies, and point-of-care molecular diagnostic methods to treat the patient. For instance, the Office for National Statistics, a recognized national statistics institute in the UK, reported that as of the week ending December 9, 2022, the rate of infection rose among people aged 35 to 69 years and also increased for those in school years 12 to 24 years. Therefore, the swift rise in infectious and respiratory diseases and subsequent fatalities will stimulate the point-of-care-molecular diagnostics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7046&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Point-Of-Care Molecular Diagnostics Market?
Technology advancements are one primary trend gaining traction in the point-of-care molecular diagnostics market. Numerous leading corporations in this market are making efforts to deliver high-tech solutions, solidifying their market dominance. They are employing innovative point-of-care molecular diagnostics technologies and relevant services, including enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), mass spectrometry (MS), in situ hybridizations, spectral karyotyping imaging, DNA microarrays, among others. These technologies are implemented in POC devices to expedite analysis times and reduce costs. For example, Sensible Diagnostics, a diagnostics firm from the US, introduced a 10-minute point-of-care PCR system in May 2023. The company is leveraging the experience gained in diagnostics by Curative during the pandemic. The company revealed that it has conducted over two million molecular point-of-care COVID-19 tests and its PCR platform returns results in just 10 minutes.

How Is the Point-Of-Care Molecular Diagnostics Market Segmented?
The point-of-care molecular diagnostics market covered in this report is segmented -

1) By Product And Service: Assays And Kits, Instruments And Analyzers, Software And Services
2) By Technology: Reverse Transcription - Polymerase Chain Reaction (RT-PCR), In Situ Hybridization, Sequencing
3) By Application: Respiratory Diseases, Hospital Acquired Infections (HAIs), Cancer/Oncology, Hepatitis, Hematology
4) By End-User: Decentralized Labs, Hospitals, Home Care, Assisted Living Healare Facilities

Subsegments:
1) By Assays And Kits: Nucleic Acid Amplification Tests (NAATs), Rapid Diagnostic Tests, Molecular Detection Kits, Reagents And Consumables
2) By Instruments And Analyzers: PCR Machines, Microfluidic Devices, Sequencers, Point-of-Care Analyzers
3) By Software And Services: Data Management Software, Cloud-Based Solutions, Technical Support And Maintenance Services, Consultation And Training Services

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=7046&type=smp

Which Companies Are Leading the Charge in Point-Of-Care Molecular Diagnostics Market Innovation?
Major companies operating in the point-of-care molecular diagnostics market include Abbott Laboratories, F Hoffmann-La Roche Ltd., BioMérieux SA, Danaher Corporation, Quidel Corporation, BioMerieux SA, Bio-Rad Laboratories Inc., Sysmex Corporation, Illumina Inc., Myriad Genetics Inc., Siemens Healare GmbH, Almac Group, Biogenex Laboratories Inc., Cepheid Inc., Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Prometheus Laboratories Inc., Ventana Medical Systems Inc., Vermillion Inc., Guardant Health Inc., Exact Sciences Corporation, Biocartis Group NV, ArcherDx Inc., Bio-Techne Corporation, AccuBiotech Co. Ltd., Becton, inson and Company, Chembio Diagnostics Inc., Credo Diagnostics Biomedical Pvt. Ltd., EKF Diagnostics, GenePOC Inc.

Which Regions Are Leading the Global Point-Of-Care Molecular Diagnostics Market in Revenue?
North America was the largest region in the point-of-care molecular diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point-of-care molecular diagnostics market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7046

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email:saumyas@tbrc.info
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.